Think Growth. Think IPOX®.
We offer specialized solutions for investors seeking exposure to New Listings - a proxy for economic growth and innovation.
Upcoming Global IPOs
The IPOX® Newsletters
IPO News
Several companies are preparing IPOs globally. Highlights include Klarna's $20B U.S. IPO, Pony AI targeting a $4.48B Nasdaq valuation, and Venture Global LNG raising $3B. In Europe, VEON plans to list Kyivstar, and Carlyle considers a $4B IPO for Flender. Asia sees IPOs from Mokingran Jewellery, Dmall, and Adaro Energy, among others. Meanwhile, Middle Eastern IPOs feature Talabat’s $1B offering and UIHC's $264M debut. Key sectors include fintech, energy, transportation, and tech.
In 2025, notable upcoming IPOs include U.S. AI cloud provider CoreWeave with support from Morgan Stanley, and Canadian pharmaceutical firm Apotex. Europe's Studenac targets dual listings in Zagreb and Warsaw, while Asia sees Japan's Kioxia and Australia’s Cuscal filing. China’s CiDi and GoerTek plan Hong Kong IPOs, and MENA highlights UAE’s Lulu Retail on the ADX. Major expansions and sector-specific listings underscore a globally active IPO landscape.
Armis, a U.S.-based cybersecurity firm, secured $200 million in funding, elevating its valuation to $4.6 billion ahead of a 2026 IPO. South African retailer Pick n Pay plans the largest African IPO of the year by listing its discount chain, Boxer, aiming to raise $452 million to reduce debt. UAE's United International Holding Company seeks $265 million through an IPO on Tadawul to support United Electronics Company.
IPOX® in the News
IPOX® CEO Josef Schuster, portfolio manager and subadvisor to the Rakuten Global IPO Stock Fund, was featured in Japan’s Nikkei Newspaper (日本経済新聞), talking about Reddit’s impressive post-IPO growth, underscoring IPOX's focus on identifying high-potential companies in the evolving global IPO landscape.
IPOX® Research Analyst Dr. Lukas Muehlbauer commented on Septerna's upsized U.S. IPO as the Goldman Sachs-backed drug developer targets a valuation of $743.1 million. Septerna, originally planning to offer 10.9 million shares within a $15-$17 range, has now increased its offering to 15.3 million shares, pricing them at $18 each, to raise approximately $275 million. This move reflects positive investor sentiment for biotech IPOs, which have seen strong performances in the U.S. market this fall.
In a recent Reuters article, IPOX® CEO Dr. Josef Schuster highlighted the strategic timing behind Ingram Micro's return to the U.S. stock market, as the global technology distributor seeks a valuation of up to $5.42 billion. Schuster emphasized that private equity firms, like Ingram's backer Platinum Equity, are capitalizing on favorable market conditions, strong demand, and the opportunity to monetize their investments.
In a recent Reuters article, IPOX® Research Analyst Dr. Lukas Muehlbauer discussed the strong debut of Upstream Bio (UPB.O) in the IPO market. The Waltham, Massachusetts-based drug developer saw its stock rise 26.5% above the IPO price, giving it a market value of $1.05 billion.
In a recent Reuters article, IPOX® research analyst Lukas Muehlbauer highlighted strong institutional and retail demand for Bicara Therapeutics' IPO, which raised $315 million after upsizing twice. Bicara’s shares surged 46% in its debut, driven by confidence in its lead anti-cancer drug and notable backing from TPG and Biocon.